Literature DB >> 33690612

Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma.

Massa Saab1, Denis Mestivier1,2, Masoudreza Sohrabi3, Christophe Rodriguez2,3,4, Mahmood Reza Khonsari3, Amirhossein Faraji3, Iradj Sobhani1,2,3,4,5.   

Abstract

Extrahepatic cholangiocarcinoma (CCA) accounts for 3% of digestive cancers. The role of biliary microbiota as an environment-related modulator has been scarcely investigated in CCA, and the putative impact of associated diseases has not been yet assessed. We characterized the biliary microbiota in CCA patients in order to identify a specific CCA-related dysbiosis. The biliary effluents were collected through an endoscopic retrograde pancreatic cholangiography (ERCP) examination involving 28 CCA and 47 patients with gallstones, herein considered as controls. The biliary effluents were submitted to bacterial DNA extraction and 16S rRNA sequencing, using Illumina technology. Overall, 32% of CCA and 22% of controls displayed another associated disease, such as diabetes, pancreatitis, inflammatory bowel disease, or primary sclerosing cholangitis. Such associated diseases were considered in the comparisons that were made. Principal coordinate analysis (PCoA) detected a significant disparity of biliary microbiota composition between CCA patients and controls without an associated disease. Amongst the most abundant phyla, Proteobacteria did not significantly differ between CCA patients and controls, whereas Firmicutes levels were lower and Bacteroidetes higher in CCAs' biliary microbiota than in the controls' microbiota. The most abundant genera were Enterococcus, Streptococcus, Bacteroides, Klebsiella, and Pyramidobacter in CCA's biliary microbiota. Additionally, levels of Bacteroides, Geobacillus, Meiothermus, and Anoxybacillus genera were significantly higher in CCA patients' biliary microbiota, without an associated disease, in comparison with controls. A specific CCA-related dysbiosis was identified as compared to controls independently from associated diseases. This suggests that a microorganism community may be involved in CCA pathogenesis.

Entities:  

Year:  2021        PMID: 33690612     DOI: 10.1371/journal.pone.0247798

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  7 in total

1.  Gut mucosal microbiota profiles linked to colorectal cancer recurrence.

Authors:  Rui-Xue Huo; Yi-Jia Wang; Shao-Bin Hou; Wei Wang; Chun-Ze Zhang; Xue-Hua Wan
Journal:  World J Gastroenterol       Date:  2022-05-14       Impact factor: 5.374

2.  Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma.

Authors:  Katsuyuki Miyabe; Vinay Chandrasekhara; Nicha Wongjarupong; Jun Chen; Lu Yang; Stephen Johnson; Nicholas Chia; Marina Walther-Antonio; Janet Z Yao; Sean C Harrington; Cynthia K Nordyke; John E Eaton; Andrea A Gossard; Sharad Oli; Hamdi A Ali; Sravanthi Lavu; Nasra H Giama; Fatima A Hassan; Hawa M Ali; Felicity T Enders; Sumera I Ilyas; Gregory J Gores; Mark D Topazian; Purna C Kashyap; Lewis R Roberts
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

Review 3.  The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis.

Authors:  Maruhen A D Silveira; Steve Bilodeau; Tim F Greten; Xin Wei Wang; Giorgio Trinchieri
Journal:  Trends Cancer       Date:  2022-03-21

Review 4.  Biliary Diseases from the Microbiome Perspective: How Microorganisms Could Change the Approach to Benign and Malignant Diseases.

Authors:  Cecilia Binda; Giulia Gibiino; Chiara Coluccio; Monica Sbrancia; Elton Dajti; Emanuele Sinagra; Gabriele Capurso; Vittorio Sambri; Alessandro Cucchetti; Giorgio Ercolani; Carlo Fabbri
Journal:  Microorganisms       Date:  2022-01-28

5.  Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles.

Authors:  Sirinya Sitthirak; Manida Suksawat; Jutarop Phetcharaburanin; Arporn Wangwiwatsin; Poramate Klanrit; Nisana Namwat; Narong Khuntikeo; Attapol Titapun; Apiwat Jarearnrat; Sakkarn Sangkhamanon; Watcharin Loilome
Journal:  PeerJ       Date:  2022-08-16       Impact factor: 3.061

Review 6.  Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances.

Authors:  Hao Qin; Baowen Yuan; Wei Huang; Yan Wang
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

7.  A systematic review on omics data (metagenomics, metatranscriptomics, and metabolomics) in the role of microbiome in gallbladder disease.

Authors:  Paola Di Carlo; Nicola Serra; Rosa Alduina; Riccardo Guarino; Antonio Craxì; Anna Giammanco; Teresa Fasciana; Antonio Cascio; Consolato M Sergi
Journal:  Front Physiol       Date:  2022-08-30       Impact factor: 4.755

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.